|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer occurred in a family with hereditary nonpolyposis colon carcinoma (HNPCC; Lynch syndrome) carrying an MLH1 mutation (IVS17-3G>C).
|
15993273 |
2005 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A combinatorial therapy with hesperetin targeting ABL1, DNMT3B, and MLH1 may be effective in circumventing chemoresistance in breast cancer.
|
31659695 |
2019 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A high proportion of patients with previous breast cancer (4 of 6 patients) had hMLH1-defective colorectal carcinomas.
|
14576472 |
2003 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
After allocation of mutation status, the cumulative risk of breast cancer to 70 years in MLH1 carriers was 18.6% (95% CI 11.3 to 25.9)).
|
26101330 |
2015 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
An intronic mutation in MLH1 associated with familial colon and breast cancer.
|
20717847 |
2011 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%. n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
|
17959715 |
2008 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carriers of both germline mutations in breast cancer genes BRCA1 or BRCA2 and in mismatch repair (MMR) genes MLH1, MSH2, MSH6 or PMS2 are very rare.
|
23164213 |
2012 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Conversely, variants in the BRIP1 and RAD51C ovarian cancer risk genes; the MRE11A, RAD50, and NBN MRN complex genes; the MLH1 and PMS2 mismatch repair genes; and NF1 were not associated with increased risks of breast cancer.
|
28418444 |
2017 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Decrease in the expression levels of TOP2A, MSH2 and MLH1 may play significant roles in the development of chemotherapeutic resistance to etoposide in breast cancer.
|
22285073 |
2012 |
|
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Down regulation of MLH1 gene expression/loss of the MLH1 protein (OR 12; CI 2.8-53.1) was observed in BC cases, illustrating its potential role in disease development.
|
31701475 |
2020 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Epigenetic silencing of essential components of DNA repair pathways is a common event in many tumor types, and comprise O6-methylguanine-DNA methyltransferase (MGMT), human mut L homolog 1 (hMLH1), Werner syndrome gene (WRN), breast cancer susceptibility gene 1 (BRCA1), and genes of the Fanconi anemia pathway.
|
19671858 |
2009 |
|
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
First, the alterations (deletion/methylation/expression) of MLH1 and MSH2 were analyzed in 45 neoadjuvant chemotherapy (NACT)-treated and 133 pretherapeutic BC samples.
|
30481381 |
2019 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In a large-enrollment, sophomore-level laboratory course, groups of three to four students were assigned a gene associated with either breast cancer (brc-1), Wilson disease (cua-1), ovarian dysgenesis (fshr-1), or colon cancer (mlh-1).
|
22665589 |
2012 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In addition to the BRCA1 promoter region, this work identified regions with variable methylation at multiple breast cancer susceptibility genes including PALB2 and MLH1.
|
27902704 |
2016 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In Caucasians, breast cancer risk was significantly associated with ADPRT 762VV [odds ratio (OR) = 1.45; 95% confidence interval (CI) = 1.03, 2.03], APE1 148DD (OR = 1.44; 95% CI = 1.03, 2.00), MLH1 219II/IV (OR = 1.87; 95% CI = 1.11, 3.16) and ERCC4 415QQ (OR = 8.64; 95% CI = 1.04, 72.02) genotypes.
|
18701435 |
2008 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Loss of the wild-type hMLH1 allele was detected in both breast tumors, thus suggesting that the MMR defect contributed to the development of the breast cancer.
|
23695190 |
2014 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our data show that women with minor alleles in both MSH2 and MLH1 could be at increased breast cancer risk.
|
23852586 |
2014 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.
|
15958648 |
2005 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our study investigates the relationship between loss of MSH2 or MLH1 function and sensitivity to the topoisomerase I and II poisons, and to the taxanes, 2 classes of cytotoxic drugs commonly used in breast cancer.
|
11477562 |
2001 |
|
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our study shows that a lack of hMLH1 expression may play a role in drug resistance, especially in the CMF group, and immunohistochemical assay for MMR protein can be used as a convenient tool for evaluating chemotherapeutic response in patients with breast cancer.
|
14717755 |
2004 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Seven single nucleotide polymorphisms (SNPs) (rs3856806 in PPARG, rs7014346 in POU5F1P1, rs989902 in PTPN13, rs1801278 in IRS1, rs7003146 in TCF7L2, rs1503185 in PTPRJ, and rs63750447 in MLH1) were genotyped in Han Chinese subjects, including 216 patients with breast cancer and 216 matched controls, using the Sequenom MassARRAY platform.
|
24338422 |
2013 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Significant differences in allele frequencies between cases and controls were observed for ID3 (inhibitor of DNA binding), p = 0.05, HPN (hepsin), p = 0.009, BCAS1 (breast carcinoma amplified sequence 1), p = 0.007, CAV2 (caveolin 2), p = 0.007, EMP3 (epithelial membrane protein 3), p < 0.0001, and MLH1 (mutL homolog 1), p < 0.0001.
|
15583422 |
2004 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Statistical analysis demonstrated that MLH1 and MSH2 deficiency may lead breast cancer progression to advanced stage, correlated with tumor focality (MLH1 P = 0.001; MSH2 P = 0.002) and chemotherapy (MLH1 P = 0.01; MSH2 P = 0.04).
|
30149959 |
2019 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The high frequency of microsatellite instability in lobular breast cancers, coupled with increased risk of breast cancer associated with germline mismatch repair gene mutations raises the possibility that mutations MSH2 or MLH1 might confer susceptibility to LCIS.
|
11369138 |
2001 |